Vaccine design: Emerging concepts and renewed optimism

Current Opinion in Biotechnology

Volumn 24, Issue 6, 2013, Pages 1078-1088

  Grimm, Sebastian K ^a   Ackerman, Margaret E ^a,b  

^a DARTMOUTH COLLEGE   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DELIVERY SYSTEMS; IMMUNE RESPONSE; IMMUNE SURVEILLANCE; MALARIA VACCINE; MEDICAL INTERVENTION; MOLECULAR INSIGHTS; PROTECTIVE IMMUNITIES; SYSTEMS BIOLOGY;

VACCINES;

DISEASES;

DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LIPOSOME; MALARIA VACCINE; NANOPARTICLE; VACCINE;

B LYMPHOCYTE; DRUG DESIGN; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INFECTION PREVENTION; INFLUENZA; INNATE IMMUNITY; MALARIA; MOLECULAR DYNAMICS; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; T LYMPHOCYTE; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; ANTIGEN PRESENTATION; B-LYMPHOCYTES; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNITY, INNATE; IMMUNODOMINANT EPITOPES; INDIVIDUALIZED MEDICINE; MALARIA VACCINES; SYSTEMS BIOLOGY; T-LYMPHOCYTES; VACCINES;

EID: 84887626348     PISSN: 09581669     EISSN: 18790429     Source Type: Journal    
DOI: 10.1016/j.copbio.2013.02.015     Document Type: Review

References (87)

1. Watson D.S., Endsley A.N., Huang L. Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. Vaccine 2012, 30:2256-2272. 10.1016/j.vaccine.2012.01.070.
2. Tatsis N., Ertl H.C. Adenoviruses as vaccine vectors. Mol Ther 2004, 10:616-629. 10.1016/j.ymthe.2004.07.013.
3. Flemming A. Vaccines: self-amplifying RNA in lipid nanoparticles: a next-generation vaccine?. Nat Rev Drug Discov 2012, 11:748-749. 10.1038/nrd3854.
4. Burton D.R. Scaffolding to build a rational vaccine design strategy. Proc Natl Acad Sci U S A 2010, 107:17859-17860. 10.1073/pnas.1012923107.
5. Haynes B.F., Kelsoe G., Harrison S.C., Kepler T.B. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol 2012, 30:423-433. 10.1038/nbt.2197.
6. Sette A., Rappuoli R. Reverse vaccinology: developing vaccines in the era of genomics. Immunity 2010, 33:530-541. 10.1016/j.immuni.2010.09.017.
7. Seib K.L., Zhao X., Rappuoli R. Developing vaccines in the era of genomics: a decade of reverse vaccinology. Clin Microbiol Infect 2012, 18(Suppl 5):109-116. 10.1111/j.1469-0691.2012.03939.x.
8. Rodriguez-Ortega M.J., Norais N., Bensi G., Liberatori S., Capo S., Mora M., Scarselli M., Doro F., Ferrari G., Garaguso I., et al. Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome. Nat Biotechnol 2006, 24:191-197. 10.1038/nbt1179.
9. Maione D., Margarit I., Rinaudo C.D., Masignani V., Mora M., Scarselli M., Tettelin H., Brettoni C., Iacobini E.T., Rosini R., et al. Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science 2005, 309:148-150. 10.1126/science.1109869.
10. Moriel D.G., Bertoldi I., Spagnuolo A., Marchi S., Rosini R., Nesta B., Pastorello I., Corea V.A., Torricelli G., Cartocci E., et al. Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli. Proc Natl Acad Sci U S A 2010, 107:9072-9077. 10.1073/pnas.0915077107.
11. Goodswen S.J., Kennedy P.J., Ellis J.T. A guide to in silico vaccine discovery for eukaryotic pathogens. Brief Bioinform 2012, [epub ahead of print]. 10.1093/bib/bbs066.
12. Finco O., Frigimelica E., Buricchi F., Petracca R., Galli G., Faenzi E., Meoni E., Bonci A., Agnusdei M., Nardelli F., et al. Approach to discover T- and B-cell antigens of intracellular pathogens applied to the design of Chlamydia trachomatis vaccines. Proc Natl Acad Sci U S A 2011, 108:9969-9974. 10.1073/pnas.1101756108.
13. Galli G., Medini D., Borgogni E., Zedda L., Bardelli M., Malzone C., Nuti S., Tavarini S., Sammicheli C., Hilbert A.K., et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci U S A 2009, 106:3877-3882. 10.1073/pnas.0813390106.
14. Gaucher D., Therrien R., Kettaf N., Angermann B.R., Boucher G., Filali-Mouhim A., Moser J.M., Mehta R.S., Drake D.R., Castro E., et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 2008, 205:3119-3131. 10.1084/jem.20082292.
15. Querec T.D., Akondy R.S., Lee E.K., Cao W., Nakaya H.I., Teuwen D., Pirani A., Gernert K., Deng J., Marzolf B., et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 2009, 10:116-125. 10.1038/ni.1688.
16. Nakaya H.I., Wrammert J., Lee E.K., Racioppi L., Marie-Kunze S., Haining W.N., Means A.R., Kasturi S.P., Khan N., Li G.M., et al. Systems biology of vaccination for seasonal influenza in humans. Nat Immunol 2011, 12:786-795. 10.1038/ni.2067.
17. Corey L., Nabel G.J., Dieffenbach C., Gilbert P., Haynes B.F., Johnston M., Kublin J., Lane H.C., Pantaleo G., Picker L.J., et al. HIV-1 vaccines and adaptive trial designs. Sci Transl Med 2011, 3:79ps13. 10.1126/scitranslmed.3001863.
18. Administration FaD. Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics, Draft Guidance. In Services USDoHaH; 2010.
19. Rappuoli R., Aderem A. A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature 2011, 473:463-469. 10.1038/nature10124.
20. Rijkers G.T., Sanders E.A., Breukels M.A., Zegers B.J. Infant B cell responses to polysaccharide determinants. Vaccine 1998, 16:1396-1400.
21. Wick G., Grubeck-Loebenstein B. The aging immune system: primary and secondary alterations of immune reactivity in the elderly. Exp Gerontol 1997, 32:401-413.
22. Ng P.P., Jia M., Patel K.G., Brody J.D., Swartz J.R., Levy S., Levy R. A vaccine directed to B cells and produced by cell-free protein synthesis generates potent antilymphoma immunity. Proc Natl Acad Sci U S A 2012, 109:14526-14531. 10.1073/pnas.1211018109.
23. Jones L.S., Peek L.J., Power J., Markham A., Yazzie B., Middaugh C.R. Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens. J Biol Chem 2005, 280:13406-13414. 10.1074/jbc.M500687200.
24. Jorgensen L., Van de Weert M., Vermehren C., Bjerregaard S., Frokjaer S. Probing structural changes of proteins incorporated into water-in-oil emulsions. J Pharm Sci 2004, 93:1847-1859. 10.1002/jps.20097.
25. Duthie M.S., Windish H.P., Fox C.B., Reed S.G. Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev 2011, 239:178-196. 10.1111/j.1600-065X.2010.00978.x.
26. Lang R., Schoenen H., Desel C. Targeting Syk-Card9-activating C-type lectin receptors by vaccine adjuvants: findings, implications and open questions. Immunobiology 2011, 216:1184-1191. 10.1016/j.imbio.2011.06.005.
27. Loo Y.M., Gale M. Immune signaling by RIG-I-like receptors. Immunity 2011, 34:680-692. 10.1016/j.immuni.2011.05.003.
28. Trumpfheller C., Longhi M.P., Caskey M., Idoyaga J., Bozzacco L., Keler T., Schlesinger S.J., Steinman R.M. Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity. J Intern Med 2012, 271:183-192. 10.1111/j.1365-2796.2011.02496.x.
29. Flynn B.J., Kastenmuller K., Wille-Reece U., Tomaras G.D., Alam M., Lindsay R.W., Salazar A.M., Perdiguero B., Gomez C.E., Wagner R., et al. Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proc Natl Acad Sci U S A 2011, 108:7131-7136. 10.1073/pnas.1103869108.
30. Tewari K., Flynn B.J., Boscardin S.B., Kastenmueller K., Salazar A.M., Anderson C.A., Soundarapandian V., Ahumada A., Keler T., Hoffman S.L., et al. Poly(I:C) is an effective adjuvant for antibody and multifunctional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and alphaDEC-CSP in non human primates. Vaccine 2010, 28:7256-7266. 10.1016/j.vaccine.2010.08.098.
31. Zaharatos G.J., Yu J., Pace C., Song Y., Vasan S., Ho D.D., Huang Y. HIV-1 and influenza antigens synthetically linked to IgG2a Fc elicit superior humoral responses compared to unmodified antigens in mice. Vaccine 2011, 30:42-50. 10.1016/j.vaccine.2011.10.056.
32. Clegg C.H., Roque R., Van Hoeven N., Perrone L., Baldwin S.L., Rininger J.A., Bowen R.A., Reed S.G. Adjuvant solution for pandemic influenza vaccine production. Proc Natl Acad Sci U S A 2012, 109:17585-17590. 10.1073/pnas.1207308109.
33. Kirnbauer R., Booy F., Cheng N., Lowy D.R., Schiller J.T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 1992, 89:12180-12184.
34. Roldao A., Mellado M.C., Castilho L.R., Carrondo M.J., Alves P.M. Virus-like particles in vaccine development. Expert Rev Vaccines 2010, 9:1149-1176. 10.1586/erv.10.115.
35. Agnandji S.T., Lell B., Soulanoudjingar S.S., Fernandes J.F., Abossolo B.P., Conzelmann C., et al. First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. N Engl J Med 2011, 365:1863-1875. 10.1056/NEJMoa1102287.
36. Hashemi H., Pouyanfard S., Bandehpour M., Noroozbabaei Z., Kazemi B., Saelens X., Mokhtari-Azad T. Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against influenza A virus challenge. PLoS ONE 2012, 7:e45765. 10.1371/journal.pone.0045765.
37. Little S.R. Reorienting our view of particle-based adjuvants for subunit vaccines. Proc Natl Acad Sci U S A 2012, 109:999-1000. 10.1073/pnas.1120993109.
38. Kasturi S.P., Skountzou I., Albrecht R.A., Koutsonanos D., Hua T., Nakaya H.I., Ravindran R., Stewart S., Alam M., Kwissa M., et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 2011, 470:543-547. 10.1038/nature09737.
39. Jewell C.M., Lopez S.C., Irvine D.J. In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particles. Proc Natl Acad Sci U S A 2011, 108:15745-15750. 10.1073/pnas.1105200108.
40. Moon J.J., Suh H., Bershteyn A., Stephan M.T., Liu H., Huang B., Sohail M., Luo S., Um S.H., Khant H., et al. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat Mater 2011, 10:243-251. 10.1038/nmat2960.
41. Geall A.J., Verma A., Otten G.R., Shaw C.A., Hekele A., Banerjee K., Cu Y., Beard C.W., Brito L.A., Krucker T., et al. Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A 2012, 109:14604-14609. 10.1073/pnas.1209367109.
42. Barnett S.W., Burke B., Sun Y., Kan E., Legg H., Lian Y., Bost K., Zhou F., Goodsell A., Zur Megede J., et al. Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant. J Virol 2010, 84:5975-5985. 10.1128/JVI. 02533-09.
43. Barouch D.H., Liu J., Li H., Maxfield L.F., Abbink P., Lynch D.M., Iampietro M.J., SanMiguel A., Seaman M.S., Ferrari G., et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012, 482:89-93. 10.1038/nature10766.
44. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., Premsri N., Namwat C., de Souza M., Adams E., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361:2209-2220. 10.1056/NEJMoa0908492.
45. Patel K.G., Swartz J.R. Surface functionalization of virus-like particles by direct conjugation using azide-alkyne click chemistry. Bioconjug Chem 2011, 22:376-387. 10.1021/bc100367u.
46. Welsh J.P., Lu Y., He X.S., Greenberg H.B., Swartz J.R. Cell-free production of trimeric influenza hemagglutinin head domain proteins as vaccine antigens. Biotechnol Bioeng 2012, 109:2962-2969. 10.1002/bit.24581.
47. Anderson T.K., Laegreid W.W., Cerutti F., Osorio F.A., Nelson E.A., Christopher-Hennings J., Goldberg T.L. Ranking viruses: measures of positional importance within networks define core viruses for rational polyvalent vaccine development. Bioinformatics 2012, 28:1624-1632. 10.1093/bioinformatics/bts181.
48. Barouch D.H., O'Brien K.L., Simmons N.L., King S.L., Abbink P., Maxfield L.F., Sun Y.H., La Porte A., Riggs A.M., Lynch D.M., et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 2010, 16:319-323. 10.1038/nm.2089.
49. Nielsen M., Lund O., Buus S., Lundegaard C. MHC class II epitope predictive algorithms. Immunology 2010, 130:319-328. 10.1111/j.1365-2567.2010.03268.x.
50. Lundegaard C., Lund O., Nielsen M. Predictions versus high-throughput experiments in T-cell epitope discovery: competition or synergy?. Expert Rev Vaccines 2012, 11:43-54. 10.1586/erv.11.160.
51. Hartman I.Z., Kim A., Cotter R.J., Walter K., Dalai S.K., Boronina T., Griffith W., Lanar D.E., Schwenk R., Krzych U., et al. A reductionist cell-free major histocompatibility complex class II antigen processing system identifies immunodominant epitopes. Nat Med 2010, 16:1333-1340. 10.1038/nm.2248.
52. Lazaro E., Kadie C., Stamegna P., Zhang S.C., Gourdain P., Lai N.Y., Zhang M., Martinez S.A., Heckerman D., Le Gall S. Variable HIV peptide stability in human cytosol is critical to epitope presentation and immune escape. J Clin Invest 2011, 121:2480-2492. 10.1172/JCI44932.
53. Ndhlovu Z.M., Piechocka-Trocha A., Vine S., McMullen A., Koofhethile K.C., Goulder P.J., Ndung'u T., Barouch D.H., Walker B.D. Mosaic HIV-1 Gag antigens can be processed and presented to human HIV-specific CD8+ T cells. J Immunol 2011, 186:6914-6924. 10.4049/jimmunol.1004231.
54. Santra S., Muldoon M., Watson S., Buzby A., Balachandran H., Carlson K.R., Mach L., Kong W.P., McKee K., Yang Z.Y., et al. Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens. Virology 2012, 428:121-127. 10.1016/j.virol.2012.03.012.
55. Fenimore P.W., Muhammad M.A., Fischer W.M., Foley B.T., Bakken R.R., Thurmond J.R., Yusim K., Yoon H., Parker M., Hart M.K., et al. Designing and testing broadly-protective filoviral vaccines optimized for cytotoxic T-lymphocyte epitope coverage. PLoS ONE 2012, 7:e44769. 10.1371/journal.pone.0044769.
56. Nunes A., Nogueira P.J., Borrego M.J., Gomes J.P. Adaptive evolution of the Chlamydia trachomatis dominant antigen reveals distinct evolutionary scenarios for B- and T-cell epitopes: worldwide survey. PLoS ONE 2010, 5. 10.1371/journal.pone.0013171.
57. Yusim K., Fischer W., Yoon H., Thurmond J., Fenimore P.W., Lauer G., Korber B., Kuiken C. Genotype 1 and global hepatitis C T-cell vaccines designed to optimize coverage of genetic diversity. J Gen Virol 2010, 91:1194-1206. 10.1099/vir.0.017491-0.
58. Yewdell J.W., Bennink J.R. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol 1999, 17:51-88. 10.1146/annurev.immunol.17.1.51.
59. Welsh R.M., Fujinami R.S. Pathogenic epitopes, heterologous immunity and vaccine design. Nat Rev Microbiol 2007, 5:555-563. 10.1038/nrmicro1709.
60. Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol 2011, 29:621-663. 10.1146/annurev-immunol-031210-101400.
61. Lindqvist M., van Lunzen J., Soghoian D.Z., Kuhl B.D., Ranasinghe S., Kranias G., Flanders M.D., Cutler S., Yudanin N., Muller M.I., et al. Expansion of HIV-specific T follicular helper cells in chronic HIV infection. J Clin Invest 2012, 122:3271-3280. 10.1172/JCI64314.
62. Moon J.J., Suh H., Li A.V., Ockenhouse C.F., Yadava A., Irvine D.J. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction. Proc Natl Acad Sci U S A 2012, 109:1080-1085. 10.1073/pnas.1112648109.
63. Lee S.K., Rigby R.J., Zotos D., Tsai L.M., Kawamoto S., Marshall J.L., Ramiscal R.R., Chan T.D., Gatto D., Brink R., et al. B cell priming for extrafollicular antibody responses requires Bcl-6 expression by T cells. J Exp Med 2011, 208:1377-1388. 10.1084/jem.20102065.
64. Gilbert S.C. T-cell-inducing vaccines-what's the future. Immunology 2012, 135:19-26. 10.1111/j.1365-2567.2011.03517.x.
65. Plotkin S.A. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010, 17:1055-1065. 10.1128/CVI. 00131-10.
66. Dormitzer P.R., Grandi G., Rappuoli R. Structural vaccinology starts to deliver. Nat Rev Microbiol 2012, 10:807-813. 10.1038/nrmicro2893.
67. Beernink P.T., Shaughnessy J., Braga E.M., Liu Q., Rice P.A., Ram S., Granoff D.M. A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J Immunol 2011, 186:3606-3614. 10.4049/jimmunol.1003470.
68. Karalewitz A.P., Barbieri J.T. Vaccines against botulism. Curr Opin Microbiol 2012, 15:317-324. 10.1016/j.mib.2012.05.009.
69. Nuccitelli A., Cozzi R., Gourlay L.J., Donnarumma D., Necchi F., Norais N., Telford J.L., Rappuoli R., Bolognesi M., Maione D., et al. Structure-based approach to rationally design a chimeric protein for an effective vaccine against Group B Streptococcus infections. Proc Natl Acad Sci U S A 2011, 108:10278-10283. 10.1073/pnas.1106590108.
70. Swanson K.A., Settembre E.C., Shaw C.A., Dey A.K., Rappuoli R., Mandl C.W., Dormitzer P.R., Carfi A. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci U S A 2011, 108:9619-9624. 10.1073/pnas.1106536108.
71. McCarthy J.S., Marjason J., Elliott S., Fahey P., Bang G., Malkin E., Tierney E., Aked-Hurditch H., Adda C., Cross N., et al. A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide(R) ISA 720. PLoS ONE 2011, 6:e24413. 10.1371/journal.pone.0024413.
72. Hviid L. The role of Plasmodium falciparum variant surface antigens in protective immunity and vaccine development. Hum Vaccin 2010, 6:84-89.
73. Asante K.P., Abdulla S., Agnandji S., Lyimo J., Vekemans J., Soulanoudjingar S., Owusu R., Shomari M., Leach A., Jongert E., et al. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Lancet Infect Dis 2011, 11:741-749. 10.1016/S1473-3099(11)70100-1.
74. Scarselli M., Arico B., Brunelli B., Savino S., Di Marcello F., Palumbo E., Veggi D., Ciucchi L., Cartocci E., Bottomley M.J., et al. Rational design of a meningococcal antigen inducing broad protective immunity. Sci Transl Med 2011, 3:91ra62. 10.1126/scitranslmed.3002234.
75. Wei C.J., Boyington J.C., McTamney P.M., Kong W.P., Pearce M.B., Xu L., Andersen H., Rao S., Tumpey T.M., Yang Z.Y., et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 2010, 329:1060-1064. 10.1126/science.1192517.
76. Bommakanti G., Citron M.P., Hepler R.W., Callahan C., Heidecker G.J., Najar T.A., Lu X., Joyce J.G., Shiver J.W., Casimiro D.R., et al. Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc Natl Acad Sci U S A 2010, 107:13701-13706. 10.1073/pnas.1007465107.
77. Schneemann A., Speir J.A., Tan G.S., Khayat R., Ekiert D.C., Matsuoka Y., Wilson I.A. A virus-like particle that elicits cross-reactive antibodies to the conserved stem of influenza virus hemagglutinin. J Virol 2012, 86:11686-11697. 10.1128/JVI. 01694-12.
78. Wang T.T., Tan G.S., Hai R., Pica N., Petersen E., Moran T.M., Palese P. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog 2010, 6:e1000796. 10.1371/journal.ppat.1000796.
79. Wang T.T., Tan G.S., Hai R., Pica N., Ngai L., Ekiert D.C., Wilson I.A., Garcia-Sastre A., Moran T.M., Palese P. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci U S A 2010, 107:18979-18984. 10.1073/pnas.1013387107.
80. Ofek G., Guenaga F.J., Schief W.R., Skinner J., Baker D., Wyatt R., Kwong P.D. Elicitation of structure-specific antibodies by epitope scaffolds. Proc Natl Acad Sci U S A 2010, 107:17880-17887. 10.1073/pnas.1004728107.
81. McLellan J.S., Correia B.E., Chen M., Yang Y., Graham B.S., Schief W.R., Kwong P.D. Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus. J Mol Biol 2011, 409:853-866. 10.1016/j.jmb.2011.04.044.
82. Jardine J., Kalyuzhniy O., Ota T., McGuire A., Menis S., Julien J., Falkowska E., MacPherson S., Jones M., Burton D.R., et al. Rational immunogen design to target specific germline B cell receptors. Retrovirology 2012, 9. Artn O71. 10.1186/1742-4690-9-S2-O71.
83. Haynes B.F., Gilbert P.B., McElrath M.J., Zolla-Pazner S., Tomaras G.D., Alam S.M., Evans D.T., Montefiori D.C., Karnasuta C., Sutthent R., et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012, 366:1275-1286. 10.1056/NEJMoa1113425.
84. Rolland M., Edlefsen P.T., Larsen B.B., Tovanabutra S., Sanders-Buell E., Hertz T., deCamp A.C., Carrico C., Menis S., Magaret C.A., et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 2012, 490:417-420. 10.1038/nature11519.
85. Keele B.F., Giorgi E.E., Salazar-Gonzalez J.F., Decker J.M., Pham K.T., Salazar M.G., Sun C., Grayson T., Wang S., Li H., et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 2008, 105:7552-7557. 10.1073/pnas.0802203105.
86. Kovacs J.M., Nkolola J.P., Peng H., Cheung A., Perry J., Miller C.A., Seaman M.S., Barouch D.H., Chen B. HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. Proc Natl Acad Sci U S A 2012, 109:12111-12116. 10.1073/pnas.1204533109.
87. Tong T., Crooks E.T., Osawa K., Binley J.M. HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes. J Virol 2012, 86:3574-3587. 10.1128/JVI. 06938-11.